Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance-Reference-Cited by-同舟云学术

Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance

Published:2012-10 Issue:7 Volume:1 Page:1027-1037
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Mizutani Tatsuaki,Neugebauer Nina,Putz Eva M.,Moritz Nadine,Simma Olivia,Zebedin-Brandl Eva,Gotthardt Dagmar,Warsch Wolfgang,Eckelhart Eva,Kantner Hans-Peter,Kalinke Ulrich,Lienenklaus Stefan,Weiss Siegfried,Strobl Birgit,Müller Mathias,Sexl Veronika,Stoiber Dagmar

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/onci.21284

Reference49 articles.

1. Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling

2. CD8+ T Cell–Mediated Skin Disease in Mice Lacking IRF-2, the Transcriptional Attenuator of Interferon-α/β Signaling

3. Negative regulation of IFN- / signaling by IFN regulatory factor 2 for homeostatic development of dendritic cells

4. Homeostatic erythropoiesis by the transcription factor IRF2 through attenuation of type I interferon signaling

5. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon–dependent exhaustion

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling by Type I Interferons in Immune Cells: Disease Consequences;Cancers;2024-04-22

2. Bystander activated CD8+ T cells mediate neuropathology during viral infection via antigen-independent cytotoxicity;Nature Communications;2024-02-05

3. Tissue factor binds to and inhibits interferon-α receptor 1 signaling;Immunity;2024-01

4. Type I interferon and cancer;Immunological Reviews;2023-09-04

5. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia;Journal for ImmunoTherapy of Cancer;2023-05